EYPT - EyePoint reports preliminary Q2 net product revenue $11.3M

• EyePoint Pharmaceuticals ( NASDAQ: EYPT ) will highlight historical and ongoing developments for its lead pipeline program, EYP-1901 and its Durasert platform technology, and will also provide a financial update during its Investor Day today.
• Phase 2 clinical trials for wet AMD (DAVIO 2) and non-proliferative diabetic retinopathy are expected to begin dosing patients in Q3 2022 and a Phase 2 clinical trial is planned for diabetic macular edema in 2023.
• George Elston, CFO, will provide a financial update on Q2 2022 performance with net product revenue of $11.3M for the quarter and cash and investments of $171M at June 30, 2022.
• CMS Draft Hospital Outpatient Rule does not extend pass-through status of expiring drugs which will impact reimbursement for DEXYCU ^® after Dec. 31, 2022.
• “EyePoint is helping to change the treatment paradigm of wet AMD using a ‘treat to maintain’ maintenance therapy approach with EYP-1901, an investigational sustained delivery anti-VEGF treatment,” said Nancy Lurker, CEO of EyePoint Pharmaceuticals.

For further details see: